At OncoStem Diagnostics Pvt. Ltd, we develop innovative prognostic tests that assess aggressiveness of tumours based on in-depth knowledge of tumour biology, to identify the unique characteristics of cancer recurrence risk. Since 2011, our vision is to empower the doctors with evidence-based treatment plans with our smart prognostic tests.
.png)
CanAssist Breast is a prognostic test that helps oncologists to determine the right treatment plan for each patient. The test classifies patients as 'low-risk' or 'high-risk' based on the patient's breast cancer recurrence risks over five years.
CanAssist Breast helps to identify the likelihood of breast cancer returning post-surgery. Our test classifies patients as low-risk or high-risk based on the patient's breast cancer recurrence risks over five years. The clear-cut test result provides doctors with additional information that can be used for treatment planning.
The doctor needs to prescribe CanAssist Breast once surgery is completed, and before proceeding with the cancer treatment so that the treatment can be personalized for every patient.
CanAssist Breast report is available within eight business days from the date the FFPE block is received by OncoStem.
Each patient's cancer is unique. If you have been diagnosed with early-stage, invasive breast cancer, it is likely that you may not benefit from chemotherapy. Large scale studies have shown that many early-stage patients are over- treated. Once your risk of breast cancer recurrence is known, you can consult your doctor to personalize your treatment plan and possibly avoid the side effects of chemotherapy.
Our vision is to empower the doctors with evidence-based treatment plans with our smart prognostic tests.
